Revenue Recognition

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated third-party revenue in the following geographic locations⁽¹⁾during each of the periods presented below (in millions):



	Year Ended
	December 31, 2019		December 31, 2018		December 31, 2017
U.S.	$	3,225.6	$	3,098.3	$	3,272.3
Europe⁽²⁾	1,335.8		1,347.6		1,343.6
All other countries⁽³⁾	276.0		285.8		330.3
Total net sales	$	4,837.4	$	4,731.7	$	4,946.2

(1) The net sales by geography is derived from the location of the entity that sells to a third party.


(2)	Includes Ireland net sales of $23.4 million, $25.7 million, and $30.4 million for the years ended December 31, 2019, December 31, 2018, and December 31, 2017, respectively.

(3) Includes revenue generated primarily in Israel, Mexico, Australia, and Canada.

Product Category

We re-aligned our product categories in our CSCA and CSCI segments as of December 31, 2019. The re-alignment standardizes our categories and product level detail to provide consistency. This transformative step will optimize the way in which management reports and evaluates our business.

The following is a summary of our revenue by category (in millions), comparative periods reflect the product category re-alignment:



	Year Ended
	December 31, 2019		December 31, 2018		December 31, 2017
CSCA⁽¹⁾
Upper respiratory	$	515.2	$	492.5	$	485.4
Digestive health	413.9		403.6		411.5
Nutrition	394.4		432.4		423.6
Pain and sleep-aids	383.6		388.1		364.8
Healthy lifestyle	352.4		333.6		341.0
Skincare and personal hygiene	182.9		164.1		163.5
Oral self-care	106.4		—		—
Animal health	43.7		93.9		141.3
Vitamins, minerals, and supplements	28.6		26.1		38.0
Other CSCA⁽²⁾	66.6		77.3		60.8
Total CSCA	2,487.7		2,411.6		2,429.9
CSCI
Skincare and personal hygiene	371.6		396.5		401.8
Upper respiratory	276.8		276.5		270.8
Vitamins, minerals, and supplements	180.2		187.2		177.9
Healthy lifestyle	173.8		180.7		182.5
Pain and sleep-aids	167.9		170.0		150.8
Oral self-care	51.2		8.9		11.0
Digestive health	27.1		29.5		29.2
Other CSCI⁽³⁾	133.6		150.0		182.2
Total CSCI	1,382.2		1,399.3		1,406.2
RX	967.5		920.8		1,054.4
Other	—		—		55.7
Total net sales	$	4,837.4	$	4,731.7	$	4,946.2

(1) Includes net sales from our OTC contract manufacturing business.


(2)	Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.


(3)	Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $286.8 million and $300.5 million for the years ended December 31, 2019 and December 31, 2018, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):



	Balance Sheet Location	December 31, 2019		December 31, 2018		January 1, 2018
Short-term contract assets	Prepaid expenses and other current assets	$	26.3	$	25.5	$	20.5